NYSE:BMY
Bristol Myers Squibb
- Stock
Share Trends
Recent Transactions
Reporter | Filed at | Change (shares) |
---|---|---|
Holzer Phil M SVP and Controller Common Stock, $0.10 par value | 2024-03-12 | 2.45K 24.46% |
Hoch Lynelle President, Cell Therapy Org. Common Stock, $0.10 par value | 2024-03-12 | 1.73K 100% |
Hirawat Samit EVP,Chief Med.Offr.,Drug Dev. Common Stock, $0.10 par value | 2024-03-12 | 13.03K 27.59% |
Lenkowsky Adam EVP, Chief Commercial Officer Common Stock, $0.10 par value | 2024-03-12 | 6.12K 1,164.26% |
Leung Sandra EVP, General Counsel Common Stock, $0.10 par value | 2024-03-12 | 15.97K 4.82% |
Largest Transactions
Reporter | Filed at | Change (shares) |
---|---|---|
Bancroft Charles A EVP, Head of Integration Common Stock, $0.10 par value | 2020-03-12 | -285.90K −72.88% |
Leung Sandra EVP, General Counsel Common Stock, $0.10 par value | 2023-11-24 | -247.81K −72.62% |
Caforio Giovanni Board Chair and CEO Common Stock, $0.10 par value | 2023-02-08 | -240K −50.41% |
Leung Sandra EVP, General Counsel Common Stock, $0.10 par value | 2020-08-17 | -141.42K −24.63% |
Caforio Giovanni Board Chair and CEO Common Stock, $0.10 par value | 2023-03-14 | 65.84K 27.89% |
Transaction Log
Filing Date | Transaction Date | Reporter | Title | Post Shares | Quantity | T | Stock Class | USD |
---|---|---|---|---|---|---|---|---|
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 2.22K | 1.70K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 10.71K | 210 | F | Common Stock, $0.10 par value | -11.30K |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 181.06K | 8.04K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 377 | 97 | F | Common Stock, $0.10 par value | -5.22K |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 3.40K | 1.44K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 10.92K | 121 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 1.96K | 267 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 12.75K | 2.43K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 60.28K | 9.77K | F | Common Stock, $0.10 par value | -525.74K |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 726 | 349 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 529 | 99 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 4.84K | 4.14K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 513 | 194 | F | Common Stock, $0.10 par value | -10.44K |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 11.04K | 701 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 1.44K | 518 | F | Common Stock, $0.10 par value | -27.86K |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 7.52K | 246 | F | Common Stock, $0.10 par value | -13.23K |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 8.20K | 283 | F | Common Stock, $0.10 par value | -15.22K |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 15.18K | 6.99K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 50.78K | 660 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 70.05K | 10.20K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 12.46K | 992 | F | Common Stock, $0.10 par value | -53.36K |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 2.65K | 2.09K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 561 | 105 | F | Common Stock, $0.10 par value | -5.65K |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 628 | 628 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 1.03K | 690 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 701 | 207 | F | Common Stock, $0.10 par value | -11.13K |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 454 | 85 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 707 | 94 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 1.73K | 917 | F | Common Stock, $0.10 par value | -49.33K |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 10.34K | 187 | F | Common Stock, $0.10 par value | -10.06K |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 524 | 318 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 6.65K | 3.23K | F | Common Stock, $0.10 par value | -174.01K |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 7.92K | 994 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 7.76K | 157 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 400.95K | 23.82K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 8.48K | 201 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 377.13K | 10.09K | F | Common Stock, $0.10 par value | -542.63K |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 387.22K | 3.69K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 479.92K | 49.74K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 51.44K | 4.19K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 53.01K | 842 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 80.26K | 29.31K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 13.86K | 11.42K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 13.45K | 1.46K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 3.01K | 328 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 3.34K | 1.90K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 474 | 50 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 666 | 60 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 1.93K | 729 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Gallman Cari | EVP, Corporate Affairs | 1.43K | 494 | F | Common Stock, $0.10 par value | -26.57K |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 194.97K | 13.35K | F | Common Stock, $0.10 par value | -717.83K |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 337 | 192 | F | Common Stock, $0.10 par value | -10.33K |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 208.31K | 16.80K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 908 | 119 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Poole Ahn Amanda | EVP, Chief Human Resources | 2.42K | 976 | F | Common Stock, $0.10 par value | -52.50K |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 539 | 539 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 257 | 197 | F | Common Stock, $0.10 par value | -10.60K |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 801 | 544 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 3.78K | 3.27K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Hoch Lynelle | President, Cell Therapy Org. | 2.64K | 1.14K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 10.62K | 613 | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 10.53K | 97 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 396.84K | 4.10K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 8.68K | 1.16K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Plenge Robert M | EVP, Chief Research Officer | 11.31K | 1.44K | F | Common Stock, $0.10 par value | -77.24K |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 337.20K | 5.79K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 336.29K | 912 | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 333.80K | 2.49K | F | Common Stock, $0.10 par value | -133.94K |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 339.66K | 5.86K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 338.65K | 1.01K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 336.17K | 2.48K | F | Common Stock, $0.10 par value | -133.13K |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 371.31K | 35.14K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 359.08K | 12.23K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Leung Sandra | EVP, General Counsel | 347.39K | 11.70K | F | Common Stock, $0.10 par value | -629.07K |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 176.64K | 8.03K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 390.90K | 23.41K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 225.11K | 48.26K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 175.38K | 1.26K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 176.85K | 2.82K | F | Common Stock, $0.10 par value | -151.90K |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 173.02K | 2.35K | F | Common Stock, $0.10 par value | -126.57K |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 529.66K | 142.90K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 386.76K | 10.08K | F | Common Stock, $0.10 par value | -542.42K |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 48.97K | 1.81K | F | Common Stock, $0.10 par value | -97.20K |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 53.85K | 4.88K | M | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Caforio Giovanni | Executive Chair of the Board | 432.27K | 47.65K | F | Common Stock, $0.10 par value | -2.56M |
2024-03-12 | 2024-03-10 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 50.95K | 2.07K | F | Common Stock, $0.10 par value | -111.24K |
2024-03-12 | 2024-03-10 | Elkins David V | EVP, Chief Financial Officer | 179.68K | 1.39K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 2.44K | 570 | F | Common Stock, $0.10 par value | -30.66K |
2024-03-12 | 2024-03-10 | Lenkowsky Adam | EVP, Chief Commercial Officer | 9.88K | 3.97K | J | Common Stock, $0.10 par value | 0 |
2024-03-12 | 2024-03-10 | Holzer Phil M | SVP and Controller | 14.92K | 4.21K | M | Common Stock, $0.10 par value | 0 |
2023-11-24 | 2023-11-21 | Leung Sandra | EVP, General Counsel | 93.44K | 9.83K | J | Common Stock, $0.10 par value | 479.16K |
2023-11-24 | 2023-11-21 | Leung Sandra | EVP, General Counsel | 331.41K | 9.83K | J | Common Stock, $0.10 par value | -479.16K |
2023-11-21 | 2023-11-20 | Samuels Theodore R. Ii | Director | 35.50K | 8.50K | P | Common Stock, $0.10 par value | 423.38K |
2023-08-07 | 2023-08-03 | Plenge Robert M | EVP, Chief Research Officer | 6.58K | 732 | S | Common Stock, $0.10 par value | -44.75K |
2023-05-04 | 2023-05-03 | Vessey Rupert | EVP & President, Research | 47.75K | 50.38K | S | Common Stock, $0.10 par value | -3.38M |
2023-04-04 | 2023-04-01 | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | 3.23K | 1.69K | F | Common Stock, $0.10 par value | -117.27K |
2023-04-04 | 2023-04-01 | Mily Elizabeth | EVP, Strategy & BD | 35.87K | 2.68K | M | Common Stock, $0.10 par value | 0 |
2023-04-04 | 2023-04-01 | Mily Elizabeth | EVP, Strategy & BD | 33.19K | 2.06K | F | Common Stock, $0.10 par value | -142.71K |
2023-04-04 | 2023-04-01 | Mily Elizabeth | EVP, Strategy & BD | 34.73K | 1.14K | F | Common Stock, $0.10 par value | -78.94K |
2023-04-04 | 2023-04-01 | Mily Elizabeth | EVP, Strategy & BD | 34.06K | 3.66K | M | Common Stock, $0.10 par value | 0 |